ClinicalTrials.gg
RecruitingNCT07463651TROPHY-15Updated Mar 20, 2026

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

A Phase 3 interventional study of Gilteritinib and Sorafenib in Acute Myeloid Leukemia (AML), FLT3-ITD Mutation and Allogeneic Hematopoietic Cell Transplantation (HCT), sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 2 sites in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Planned enrollment
5th of 31
594 · median 97
Started
2026
with 2 others
Phase 3
8 of 31
3 open now
Primary completion
2028-05
later than 4 of 14 live
Registered
31st of 31
by date

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 5th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 31st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The study population consisted of FLT3-ITD-mutated AML patients who were FLT3-ITD-positive before allogeneic hematopoietic stem cell transplantation. This open-label, randomized, controlled trial enrolled participants and randomly assigned them in a 1:1 ratio to either the experimental group or the control group. The experimental group received maintenance therapy with gilteritinib, while the control group received maintenance therapy with sorafenib, with 297 cases in each group, totaling 594 enrolled subjects.

All patients' minimal residual disease (MRD) testing was sent to the designated central laboratory and uniformly performed using the PCR-NGS method to ensure consistency and comparability of the test results.

Study Visits: This study includes a screening period (within 30 days prior to HCT) and a 2-year treatment phase, with efficacy and safety follow-up until death, withdrawal of informed consent, or 2 years after the first administration of treatment, whichever occurs first.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • FLT3-ITD Mutation
  • Allogeneic Hematopoietic Cell Transplantation (HCT)
  • Maintenance Therapy
  • Gilteritinib
  • Sorafenib

Keywords

  • Acute Myeloid Leukemia
  • FLT3-ITD Mutation
  • Allogeneic Hematopoietic Cell Transplantatio
  • Maintenance therapy
  • Gilteritinib
  • sorafeni
04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and willingness to participate in this clinical study;

    • Gender is not limited, age range is 14-70 years old (including threshold);

      • score 0-2 points;

        • Diagnosed with AML through bone marrow morphology, immunology, cytogenetics, and molecular biology (MICM) typing, and confirmed to have FLT3-ITD mutation;

          • Successfully accepted allo , with no restrictions on the pre-treatment protocol, allowing any donor source [fully matched cell, unrelated donor (URD), incompatible unrelated donor, haploidentical relative donor or umbilical cord blood], allowing any graft source [umbilical cord blood, bone marrow (BM), peripheral blood (PB)]; ⑥ Patients with complete morphological remission (CR) prior to allo HSCT, and FLT3-ITD MRD positivity detected by PCR-NGS within 30 days prior to allo HSCT (defined as FLT3-ITD transcript level ≥ 10 - 6);

            ⑦ After transplantation: hematopoietic function implantation ( ≥ 500/μ L, count ≥ 20000/μ L and not dependent on infusion), oral administration of drugs, exclusion of overlap syndrome, complete donor chimerism (FDC) status, no activity requiring daily prednisone dose>0.5 mg/kg, acute ;

            ⑧ Clinical laboratory tests meet the following criteria: a. Serum creatinine ≤ 2.0 times the value; b. Total ≤ 2.5 mg/dL (excluding Gilbert syndrome patients); c. Serum and/or ALT\<3 times the upper limit of normal values;

            ⑨ Maintenance treatment should be started 60 to 90 days after transplantation;

            ⑩ Female participants must meet the following criteria: have undergone menopause (at least 1 year without menstruation) or surgical sterilization (at least 1 month ago) before screening for infertility; Or have the ability to conceive but agree not to plan pregnancy during the study period and within 6 months after the last dose; Conduct pregnancy tests during the screening period; If there is heterosexual behavior, agree to continue using local standard high-efficiency measures plus barrier method from the beginning of screening to 6 months after the last administration; Agree not to breastfeed or donate eggs during the study period and for 6 months after the last administration Male participants must meet the following requirements: male participants (even if sterilized) and their reproductive partners must use efficient contraception plus barrier method during the study period and within 127 days after the last dose; Male participants are not allowed to donate sperm during the study period and for 127 days after the last dose;

Exclusion criteria

Exclusion Criteria:

  • Allergies to Girotinib or Sorafenib, as well as any components of the therapeutic drugs used during the study period;

    • Any serious comorbidities that make patients unsuitable for participation in this study or may affect protocol compliance;

      • FLT3-ITD molecular MRD positivity before maintenance therapy;

        • Severe organ dysfunction such as organ failure occurs after hematopoietic stem cell transplantation;

          • Subjects who are positive for B surface antigen (HBsAg) and whose hepatitis B virus (HBV) DNA titer is higher than the value range of the research center, and who are judged by the researchers not suitable for this study; Individuals with positive virus (HCV) antibodies and positive peripheral blood HCV RNA; Individuals who are antibody positive; Positive syphilis test results;

            ⑥ There is evidence within the first 6 months of enrollment that the patient has other diseases or physiological conditions that may interfere with the evaluation results of this trial, or complications that seriously endanger life, including but not limited to uncontrolled infections, pulmonary arterial hypertension, severe heart failure ( grades III and IV), unstable angina or acute myocardial infarction, poorly controlled hypertension (based on hospitalization medical records diagnosis), etc;

            ⑦ Individuals with mental or neurological disorders who are unable to express their wishes correctly;

            ⑧ Individuals who have had active malignant solid tumors within the past 5 years prior to participating in this study, except for cervical cancer, localized prostate cancer in situ, and non melanoma skin cancer that have been cured;

            ⑨ Have participated in or are currently participating in other clinical trials within one month prior to enrollment;

            ⑩ Researchers have determined that individuals are not suitable to participate in this clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
594 participants (estimated)

Study arms

  • Experimental
    Arm A

    Randomization should be performed between days 60 and 90 after the day of allogeneic hematopoietic stem cell infusion (day 0 post-HCT). Participants allocated in this arm must take Gilteritinib 3 tablets (40 mg per tablet) daily in the morning, with continuous daily administration

    Drug: Gilteritinib

  • Active comparator
    Arm B

    Randomization should be performed between days 60 and 90 after the day of allogeneic hematopoietic stem cell infusion (day 0 post-HCT). Participants allocated in this arm must take sorafenib 400 mg orally, twice daily (BID), with continuous administration

    Drug: Sorafenib

Interventions

  • Randomization should be performed between days 60 and 90 after the day of allogeneic hematopoietic stem cell infusion (day 0 post-HCT). Participants allocated in this arm must take Gilteritinib 3 tablets (40 mg per tablet) daily in the morning, with continuous daily administration.

  • Randomization should be performed between days 60 and 90 after the day of allogeneic hematopoietic stem cell infusion (day 0 post-HCT). Participants allocated in this arm must take sorafenib 400 mg orally, twice daily (BID), with continuous administration

06

What researchers measure

Primary outcomes

  1. Measurable residual disease recurrence-free survival (MRD-RFS)

    The time from randomization to occurrence of hematological recurrence, molecular recurrence (FLT3-ITD mutation MRD changes from negative to positive), or death from any cause (whichever occurs first).

    Time frame: 2-year

Secondary outcomes

  1. Overall Surivival (OS)

    The time from randomazation to death

    Time frame: 2-year

  2. Molecular Recurrence

    From random to MRD-positive detected by PCR NGS of FLT3-ITD mutation

    Time frame: 2-year

  3. MFC-MRD Recurrence

    From randomization to MRD-positive detected by MFC

    Time frame: 2-year

  4. Cumulative Incidence of Relapse (CIR)

    From randomization to relapse

    Time frame: 2-year

  5. Non-Relapse Mortality (NRM)

    From randomization to death unrelated to AML

    Time frame: 2-year

  6. Chronic Graft-versus-Host Disease (cGVHD)

    From randomization to the occurence of chronic graft-versus-host disease (cGVHD)

    Time frame: 2-year

  7. Acute Graft-versus-Host Disease (aGVHD)

    From randomization to the occurence of acute graft-versus-host disease (aGVHD)

    Time frame: 2-year

  8. Graft-versus-Host Disease and Relapse-free survival (GRFS)

    From randomization to the occurence of graft-versus-host disease (GVHD), relapse or death, which occurs first

    Time frame: 2-year

  9. Relpase-Free Survival (RFS)

    From randomization to the occurence of relapse or death, which occurs first

    Time frame: 2-year

07

Study locations

2 of 2 sites recruiting
  • the First Affiliated Hosptital of Soochow University
    Suzhou, Jiangsu 215006, China
    Recruiting
    • Jia Chen, M.D., Ph.D. · Contactdrchenjia@163.com · +8651267781856
    • Jia Chen, M.D., Ph.D. · Principal investigator
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
    Recruiting
    • Xiaoxia Hu, M.D., Ph.D. · Contacthxx12276@rjh.com.cn · +862164370045
    • Xiaoxia Hu, M.D., Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — If required, IPD may be shared with approval of institutional ethic committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2028, 24 months later.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 24 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 11, 2026
StartEst.
May 1, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Mar 31, 2030
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07463651
Responsible party
CHEN Jia (Director Assisstant, Dept. Hematology, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Mar 11, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 31, 2028 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Mar 20, 2026

Study contacts

Jia Chen, MD, PhD
Contact
drchenjia@163.com
+86-512-67781856

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion